| Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma J Larkin, PA Ascierto, B Dréno, V Atkinson, G Liszkay, M Maio, M Mandalà, ... New England Journal of Medicine 371 (20), 1867-1876, 2014 | 2370 | 2014 |
| Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial PA Ascierto, GA McArthur, B Dréno, V Atkinson, G Liszkay, ... The lancet oncology 17 (9), 1248-1260, 2016 | 1095 | 2016 |
| Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial R Dummer, PA Ascierto, HJ Gogas, A Arance, M Mandala, G Liszkay, ... The Lancet Oncology 19 (5), 603-615, 2018 | 980 | 2018 |
| Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label … R Dummer, PA Ascierto, HJ Gogas, A Arance, M Mandala, G Liszkay, ... The Lancet Oncology 19 (10), 1315-1327, 2018 | 580 | 2018 |
| Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial PA Ascierto, M Del Vecchio, C Robert, A Mackiewicz, V Chiarion-Sileni, ... The Lancet Oncology 18 (5), 611-622, 2017 | 501 | 2017 |
| Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial R Dummer, D Schadendorf, PA Ascierto, A Arance, C Dutriaux, ... The Lancet Oncology 18 (4), 435-445, 2017 | 461 | 2017 |
| Prognostic impact of B-cell density in cutaneous melanoma A Ladányi, J Kiss, A Mohos, B Somlai, G Liszkay, K Gilde, Z Fejős, I Gaudi, ... Cancer Immunology, Immunotherapy 60 (12), 1729-1738, 2011 | 235 | 2011 |
| Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study C Robert, R Dummer, R Gutzmer, P Lorigan, KB Kim, M Nyakas, A Arance, ... The lancet oncology 14 (8), 733-740, 2013 | 192 | 2013 |
| Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in … PA Ascierto, R Dummer, HJ Gogas, KT Flaherty, A Arance, M Mandala, ... European Journal of Cancer 126, 33-44, 2020 | 187 | 2020 |
| 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study PA Ascierto, B Dréno, J Larkin, A Ribas, G Liszkay, M Maio, M Mandalà, ... Clinical Cancer Research 27 (19), 5225-5235, 2021 | 111 | 2021 |
| Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma. JMG Larkin, Y Yan, GA McArthur, PA Ascierto, G Liszkay, M Maio, ... Journal of Clinical Oncology 33 (15 Suppl.), 2015 | 91 | 2015 |
| FOXP3+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma A Ladányi, A Mohos, B Somlai, G Liszkay, K Gilde, Z Fejős, I Gaudi, ... Pathology & Oncology Research 16 (3), 303-309, 2010 | 91 | 2010 |
| Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management HJ Gogas, KT Flaherty, R Dummer, PA Ascierto, A Arance, M Mandala, ... European Journal of Cancer 119, 97-106, 2019 | 89 | 2019 |
| Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy T Balatoni, A Mohos, E Papp, T Sebestyén, G Liszkay, J Oláh, A Varga, ... Cancer Immunology, Immunotherapy 67 (1), 141-151, 2018 | 89 | 2018 |
| Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated … JMG Larkin, Y Yan, GA McArthur, PA Ascierto, G Liszkay, M Maio, ... Journal of Clinical Oncology 33 (15_suppl), 9006-9006, 2015 | 73 | 2015 |
| Partial breast irradiation with interstitial 60CO brachytherapy results in frequent grade 3 or 4 toxicity. Evidence based on a 12-year follow-up of 70 patients Z Póti, C Nemeskéri, A Fekésházy, G Sáfrány, G Bajzik, ZP Nagy, ... International Journal of Radiation Oncology* Biology* Physics 58 (4), 1022-1033, 2004 | 69 | 2004 |
| Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma PA Ascierto, M Del Vecchio, A Mackiewicz, C Robert, V Chiarion-Sileni, ... Journal for immunotherapy of cancer 8 (1), 2020 | 52 | 2020 |
| Immune cell profile of sentinel lymph nodes in patients with malignant melanoma–FOXP3+ cell density in cases with positive sentinel node status is associated with unfavorable … A Mohos, T Sebestyén, G Liszkay, V Plótár, S Horváth, I Gaudi, A Ladányi Journal of translational medicine 11 (1), 1-11, 2013 | 52 | 2013 |
| Relationship between sentinel lymph node status and regression of primary malignant melanoma G Liszkay, Z Orosz, G Péley, O Csuka, V Plótár, I Sinkovics, T Bánfalvi, ... Melanoma research 15 (6), 509-513, 2005 | 46 | 2005 |
| Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study R Dummer, P Queirolo, AMA Guijarro, Y Hu, D Wang, SJ de Azevedo, ... The Lancet Oncology 23 (9), 1145-1155, 2022 | 43* | 2022 |
